Xenon Pharmaceuticals Inc (NASDAQ: XENE) kicked off on Monday, up 5.51% from the previous trading day, before settling in for the closing price of $40.50. Over the past 52 weeks, XENE has traded in a range of $27.99-$50.99.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 35.90%. While this was happening, its average annual earnings per share was recorded -6.70%. With a float of $73.73 million, this company’s outstanding shares have now reached $75.37 million.
Considering the fact that the conglomerate employs 259 people, you should pay attention to its efficiency factor.
Xenon Pharmaceuticals Inc (XENE) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Xenon Pharmaceuticals Inc is 2.26%, while institutional ownership is 94.74%. The most recent insider transaction that took place on Mar 08 ’24, was worth 95,583. In this transaction Director of this company sold 2,092 shares at a rate of $45.69, taking the stock ownership to the 0 shares. Before that another transaction happened on Mar 07 ’24, when Company’s Director sold 13,000 for $46.28, making the entire transaction worth $601,615. This insider now owns 2,000 shares in total.
Xenon Pharmaceuticals Inc (XENE) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -6.70% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.90% during the next five years compared to -10.87% drop over the previous five years of trading.
Xenon Pharmaceuticals Inc (NASDAQ: XENE) Trading Performance Indicators
Take a look at Xenon Pharmaceuticals Inc’s (XENE) current performance indicators. Last quarter, stock had a quick ratio of 23.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.73, a number that is poised to hit -0.66 in the next quarter and is forecasted to reach -3.29 in one year’s time.
Technical Analysis of Xenon Pharmaceuticals Inc (XENE)
Compared to the last year’s volume of 0.4 million, its volume of 0.37 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 63.02%. Additionally, its Average True Range was 1.57.
During the past 100 days, Xenon Pharmaceuticals Inc’s (XENE) raw stochastic average was set at 40.10%, which indicates a significant decrease from 87.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 39.31% in the past 14 days, which was higher than the 34.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $43.95, while its 200-day Moving Average is $39.75. Nevertheless, the first resistance level for the watch stands at $43.50 in the near term. At $44.27, the stock is likely to face the second major resistance level. The third major resistance level sits at $45.72. If the price goes on to break the first support level at $41.28, it is likely to go to the next support level at $39.83. Now, if the price goes above the second support level, the third support stands at $39.06.
Xenon Pharmaceuticals Inc (NASDAQ: XENE) Key Stats
The company with the Market Capitalisation of 3.22 billion has total of 75,432K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -182,390 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -44,740 K.
